Please use this identifier to cite or link to this item:
Title: Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy.
Austin Authors: Wang, Yang;Mathai, Jared;Alamgeer, Muhammad;Parakh, Sagun ;Paul, Eldho;Mitchell, Paul L R ;Arulananda, Surein
Affiliation: Department of Medical Oncology, Monash Health, Clayton, Australia.
Medical Oncology
Department of Medical Oncology, Monash Health, Clayton, Australia.
Olivia Newton-John Cancer Research Institute
Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Australia.
Department of Medical Oncology, Monash Health, Clayton, Australia.;School of Clinical Sciences, Faculty of Medicine, Monash University, Clayton, Australia.;Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Australia.
Issue Date: Aug-2023
Date: 2023
Publication information: JTO Clinical and Research Reports 2023-08; 4(8)
Abstract: There are no clinically validated prognostic biomarkers in the management of extensive-stage SCLC (ES-SCLC). We explored the association between clinical characteristics and survival outcomes in patients with ES-SCLC treated with chemoimmunotherapy. In this retrospective cohort study, patients with ES-SCLC treated with first-line platinum-etoposide chemotherapy and atezolizumab were identified from medical records. Pretreatment clinical characteristics, biochemical parameters, and tumor and treatment characteristics were collected. Univariate and multivariate Cox regression were used to evaluate treatment effect on progression-free survival (PFS) and overall survival (OS). We evaluated 75 patients in total. The median PFS and OS were 6.1 months and 9.2 months, respectively. Statistically significant associations were found with lower lactate dehydrogenase and improved OS (hazard ratio [HR] = 1.0, 95% confidence interval [CI]: 1.0-1.01, p = 0.006), whereas higher age (HR = 0.94, 95% CI: 0.90-0.98, p = 0.006) and lower neutrophil-to-lymphocyte ratio (HR = 1.08, 95% CI: 1.02-1.14, p = 0.005) were associated with improved PFS. The number of chemotherapy cycles received were associated with both an improved PFS (HR = 0.57, 95% CI: 0.37-0.89, p = 0.011) and OS (HR = 0.5, 95% CI: 0.30-0.84, p = 0.008). This study highlights the important effect of chemotherapy on survival. Furthermore, the association between lactate dehydrogenase and neutrophil-to-lymphocyte ratio on survival further suggests that baseline tumor burden and optimizing sarcopenia are important factors for clinicians to consider as we seek to develop personalized treatment for this disease.
DOI: 10.1016/j.jtocrr.2023.100544
Journal: JTO Clinical and Research Reports
Start page: 100544
PubMed URL: 37529402
ISSN: 2666-3643
Type: Journal Article
Subjects: Chemoimmunotherapy
Clinical characteristics
Small cell lung cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.